| Sector |
Plastic Products
|
Compare with Sector peers |
| Industry |
Plastic Products
|
Compare with Industry peers |
| Website | http://www.bilcare.com | |
| Market Cap | 152.10 Cr. | |
| Enterprise Value(EV) | 842.03 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -5.35 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 21.33 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 31.92 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 2.02 | Calculated using Price: 64.60 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 2.35 Cr. | 23,545,231 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients. Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products. Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects. Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security It has representative offices located in It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy’s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide. For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites. Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs. In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10. |
||
Company Profile
Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.
Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.
Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.
Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.
It has representative offices located in
It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy’s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.
For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.
Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.
In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.
| 1 Day |
|
+0.70% |
| 1 Week |
|
-7.18% |
| 1 Month |
|
-14.72% |
| 3 Month |
|
-2.64% |
| 6 Month |
|
-16.59% |
| 1 Year |
|
+10.52% |
| 2 Year |
|
+157.88% |
| 5 Year |
|
+11.76% |
| 10 Year |
|
-58.87% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 4.38 | -9.38 | -14.86 | -9.09 | -12.03 | -39.29 | -274.69 | -515.03 | -11.48 | |
| Return on Capital Employed (%) | 7.96 | 3.36 | 1.16 | -1.40 | 4.40 | 1.64 | -6.38 | 4.01 | 6.41 | |
| Return on Assets (%) | 1.40 | -2.83 | -4.13 | -2.07 | -2.26 | -5.81 | -13.97 | -4.82 | -1.13 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 1,325 | 1,324 | 1,096 | 713 | 614 | 400 | -70 | 108 | 86 | 75 | |
| Non Curr. Liab. | 2,050 | 2,126 | 2,228 | 2,090 | 2,036 | 960 | 1,024 | 535 | 477 | 449 | |
| Curr. Liab. | 989 | 866 | 966 | 758 | 745 | 1,978 | 2,069 | 311 | 314 | 403 | |
| Minority Int. | 54 | 53 | 49 | 59 | 62 | 63 | 64 | 68 | 78 | 86 | |
| Equity & Liab. | 4,419 | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,023 | 955 | 1,013 | |
| Non Curr. Assets | 2,407 | 2,444 | 2,293 | 2,713 | 2,669 | 2,469 | 2,205 | 657 | 618 | 592 | |
| Curr. Assets | 2,012 | 1,924 | 2,047 | 907 | 788 | 933 | 882 | 365 | 337 | 421 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 4,419 | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,023 | 955 | 1,013 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 3,547 | 3,062 | 2,692 | 2,603 | 2,633 | 2,778 | 2,997 | 1,827 | 623 | 845 | |
| Other Income | 20 | 18 | 46 | 30 | 39 | 34 | 60 | 97 | 18 | 15 | |
| Total Income | 3,567 | 3,080 | 2,738 | 2,633 | 2,672 | 2,813 | 3,057 | 1,924 | 641 | 859 | |
| Total Expenditure | -3,175 | -2,823 | -2,507 | -2,396 | -2,445 | -2,621 | -2,829 | -1,782 | -572 | -784 | |
| PBIDT | 392 | 257 | 231 | 237 | 227 | 192 | 229 | 142 | 69 | 75 | |
| Interest | -167 | -217 | -236 | -151 | -176 | -249 | -283 | -174 | -76 | -69 | |
| Depreciation | -148 | -141 | -191 | -164 | -177 | -416 | -378 | -239 | -46 | -39 | |
| Taxation | -19 | -23 | 16 | 112 | -24 | 8 | -21 | 15 | 14 | 0 | |
| Exceptional Items | -117 | 70 | 267 | 157 | 27 | 29 | |||||
| PAT | 57 | -124 | -180 | -82 | -80 | -199 | -453 | -99 | -11 | -4 | |
| Minority Interest | -5 | 1 | 0 | -3 | -5 | -2 | -2 | -5 | -10 | -8 | |
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 40 | -113 | -216 | -85 | -85 | -201 | -458 | -104 | -21 | -13 | |
| Adjusted EPS | 22 | -52 | -76 | -36 | -36 | -85 | -193 | -44 | -9 | -5 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 92 | 227 | 314 | -315 | 177 | 300 | 98 | 206 | 256 | 72 | |
| Cash Fr. Inv. | -383 | -966 | -351 | 247 | -358 | -129 | -203 | -104 | 1,309 | 2 | |
| Cash Fr. Finan. | 285 | 661 | 48 | 119 | 149 | -155 | 91 | -103 | -1,600 | -83 | |
| Net Change | -5 | -78 | 12 | 50 | -32 | 16 | -13 | -1 | -35 | -9 | |
| Cash & Cash Eqvt | 173 | 94 | 106 | 156 | 73 | 90 | 77 | 76 | 41 | 32 |
|
Thu, 26 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Submission of Secretarial Compliance Report |
|
Wed, 25 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication of Audited Results for the quarter and year ended 31st March 22 |
|
Mon, 23 May 2022
Board Meeting Outcome for Submission Of Audited Financial Results Under Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter And Year Ended 31 March 2022. Submission of Audited Financial Results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the quarter and year ended 31 March 2022. |
| Fri, 27 May 2022 |
Opening at High
|
High Decrease 1 Month
|
High Increase 2 Years
|
CCI Bullish
|
MFI Trending Up
|
Equities
M.F.
Sectors